

Product datasheet for **TL309076**

ST3GAL5 Human shRNA Plasmid Kit (Locus ID 8869)

Product data:

Product Type:	shRNA Plasmids
Product Name:	ST3GAL5 Human shRNA Plasmid Kit (Locus ID 8869)
Locus ID:	8869
Synonyms:	SATI; SIAT9; SIATGM3S; SPDRS; ST3Gal V; ST3GalV
Vector:	pGFP-C-shLenti (TR30023)
E. coli Selection:	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection:	Puromycin
Format:	Lentiviral plasmids
Components:	ST3GAL5 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 8869). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq:	NM_001042437 , NM_003896 , NM_001354223 , NM_001354224 , NM_001354226 , NM_001354227 , NM_001354229 , NM_001354233 , NM_001354234 , NM_001354238 , NM_001354247 , NM_001354248 , NM_003896.1 , NM_003896.2 , NM_003896.3 , NM_001042437.1 , BC065936 , BC065936.1 , BC009887 , NM_001363847 , NM_001042437.2
UniProt ID:	Q9UNP4
Summary:	Ganglioside GM3 is known to participate in the induction of cell differentiation, modulation of cell proliferation, maintenance of fibroblast morphology, signal transduction, and integrin-mediated cell adhesion. The protein encoded by this gene is a type II membrane protein which catalyzes the formation of GM3 using lactosylceramide as the substrate. The encoded protein is a member of glycosyltransferase family 29 and may be localized to the Golgi apparatus. Mutation in this gene has been associated with Amish infantile epilepsy syndrome. Transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).